Research and Markets: Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/7xfkg5/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering.

The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies.

The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,

- Target / Mechanism of Action,

- Class of Compound,

- Company,

- Product Category,

- Indication,

- R&D Stage and

- additional comments with a hyperlink leading to the source of information.

Key Topics Covered

1. EGF-R Antibodies -Biosimilars and Biosuperiors

Marketed EGF-R Antibodies

- Erbitux Sales & Pipeline

- Vectibix Sales & Pipeline

- Nimotuzumab Pipeline

EGF-R Antibody Biobetters/Biosuperiors

- Engineered EGF-R Antibodies

- Bi- and Multispecific EGF-R Antibodies

- EGF-R Antibody-Drug Conjugates

EGF-R Antibody Biosimilars

- Cetuximab Biosimilars

- Panitumumab Biosimilars

2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines

Companies Mentioned

- AbbVie

- Actavis

- Amgen

- Avesthagen Pharma

- Biocon

- BioXpress

- Bristol-Myers Squibb (BMS)

- Celltrion

- Centro de Imunologica Molecular AB (CIMAB)

- CytomX Therapeutics

- Daiichi Sankyo

- Eli Lilly

- Fusion Therapeutics

- Glycotope

- Green Cross

- Hospira

- Immune Pharmaceuticals

- Immunogen

- Innogene Kalbiotech

- InnoMab

- ISU Abxis

- Janssen Pharmaceuticals

- Med Discover

- Merck GKaA

- Merrimack Pharmaceuticals

- Merus

- Oncobiologics

- Oncoscience

- Pfizer 4

- PharmaPraxis

- PlantForm

- Roche

- Shanghai Zhangjiang Biotechnology

- Sorrento Therapeutics

- Symphogen

- Takeda Pharmaceutical

- Viropro

- Zyngenia

For more information visit http://www.researchandmarkets.com/research/7xfkg5/competitor

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals